CHD/Prevention News

SAN DIEGO — Semaglutide was superior to placebo in metabolic dysfunction-associated steatohepatitis resolution and improvement in fibrosis at 72 weeks, with a safety profile consistent with previous studies, according to late-breaking data.

CHICAGO — Black and Hispanic women who adhered to components of a Mediterranean-style diet were less likely to experience any adverse pregnancy outcome, regardless of overweight or obesity status, researchers reported.

Salt substitution intervention beginning at age 40 years was cost-effective among Chinese adults with prehypertension compared with antihypertensive drug treatment alone, according to findings published in Hypertension.

The GLP-1 receptor agonist semaglutide may not only add another therapeutic option for chronic kidney disease, but it could also lead to changes in the way clinicians treat the condition.

CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.

CHICAGO — People living in historically redlined neighborhoods with poor access to healthy foods were more likely to have type 2 diabetes, hypertension, coronary heart disease and obesity, researchers reported.

CHICAGO — Emailed messages emphasizing the CV benefits of influenza vaccination improved vaccine uptake among older and younger adults in Denmark, particularly among more vulnerable patients with a history of acute MI, researchers reported.

CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.

CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.

CHICAGO — For adults at high or very high CVD risk, a monthly PCSK9 inhibitor added to maximally tolerated oral lipid-lowering therapy maintained LDL reductions of more than 60% through 72 weeks, with no signals of attenuation.